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Introduction
Memory consolidation is the process by 
which information is transferred from the 
fragile, readily-disposable state of short-
term memory, into a more robust, stable 
and interference-proof domain. This allows 
for memories to be stored and recalled over 
longer time scales, without being distorted by 
new incoming information. The importance 
of memory consolidation becomes readily 
apparent when we observe what happens in its 
absence. Patients with dementia, particularly 
Alzheimer’s disease (AD) dementia, often lose 
their ability to consolidate memory with the 
devastating consequence of being locked 
to the past, unable to fully engage with the 
changing world around them. Here, we will 
review the mechanisms underlying memory 
consolidation, and methods by which these 
could be enhanced. We will include lifestyle 
approaches, pharmacological and non-
pharmacological technical interventions 
that are emerging through our growing 
understanding of the neurobiology of 
cognition. 
Who is aected by memory 
consolidation decits?
Prominent memory impairment is a feature of 
AD. AD is a neurodegenerative disease affecting 
more than 35 million people worldwide 
costing in excess of $600 billion US per year. 
Prevalence of AD dramatically increases with 
age, affecting around 20% of those aged 
85 years [1]. Neuropathological staging and 
sensitive neuroimaging techniques tell us 
that the hippocampus is affected in the very 
earliest stages of AD [2,3]. Given the role of 
the hippocampus in memory consolidation, 
it is therefore no surprise that AD is often 
characterised by decline in memory, although 
other cognitive domains are usually affected 
by the time a diagnosis is made [4]. In other 
dementias, including dementia with Lewy 
bodies, frontotemporal dementia and vascular 
dementia, memory is also often affected, but 
this is less consistently an early finding.
Although less critical socio-economically, 
other diseases in which memory consolidation 
is affected can be equally devastating to 
the individual. The hippocampus can be 
affected irreversibly in viral encephalitis and 
is a particular target for antibodies including 
voltage-gated potassium channel antibodies 
and other paraneoplastic antibodies 
producing amnesia as part of a syndrome of 
limbic encephalitis [5]. In addition, thiamine 
deciency, recurrent seizures and hippocampal 
sclerosis can all also result in variable memory 
impairment. Many of these conditions can be 
treated, but often result in permanent memory 
consolidation impairment which would be 
potentially amenable to targeted therapy.
There is also evidence that memory 
consolidation is affected by normal ageing [6] 
and certain younger people  (e.g. students, 
scientists, doctors, news reporters) might 
benet from enhanced memory consolidation, 
raising the controversial possibility of cognitive 
enhancement in the neurologically healthy.
Mechanisms underlying memory 
consolidation
The unfortunate case of H.M. was particularly 
revealing in terms of the light it shed on 
the role of the hippocampus. After bilateral 
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surgical removal of the hippocampi, H.M was 
unable to form new long-term declarative 
memories, holding onto information for just a 
few minutes; thus, this structure was revealed 
to be a potential gateway that allowed for 
short-term memories to join previously stored 
long-term information. This is the essence of 
the two-stage theory of memory [7,8]. This 
proposes that short-term memories are initially 
stored in the hippocampus, and later, during 
consolidation, transferred to the neocortex. 
During the acquisition of new memories, this 
information is encoded in specic ensembles 
of neurones within the hippocampus. It is 
worthy to note that while H.M. was unable to 
form new declarative memory, he was actually 
able to progressively learn new motor skills, 
demonstrating the now widely-acknowledged 
divergent systems for hippocampal-
dependent declarative memory and separate 
procedural memory. We will focus in this 
review on hippocampal, declarative memory 
consolidation.
In order for consolidation of hippocampal-
dependent memories to occur, the transfer 
of information from the hippocampus to the 
neocortex must take place. Sleep – specifically, 
slow wave sleep (SWS) – is thought to provide 
a unique physiological state that allows for this 
transfer, and mounting evidence points to the 
role of sleep in facilitating long-term memory 
consolidation. Enhancements in recall are 
such that sleep provides a clear improvement 
compared to an equal amount of time spent 
awake, something which has been found in 
both animals and humans [9-11]. Therefore the 
memory enhancement provided during sleep 
is not merely due to passage of time alone. 
One of the hallmarks of SWS, and 
amongst the key events underlying memory 
consolidation, is the presence of hippocampal 
ripples. These are hippocampal field 
oscillations, reecting bursts of high frequency 
(in animals 140 – 200 Hz; in humans, 80 – 140 
Hz) population activity. Hippocampal ripples 
originate in the CA1 hippocampal subfield, 
and co-occur with a sharp-wave activity 
which is instigated by CA3 and propagates 
to CA1 via the Schaffer collaterals [12,13]. 
These hippocampal ripple events are often 
accompanied by a reactivation of recently-
acquired information, reected by reactivation 
of hippocampal neuronal patterns of activity 
that occurred during acquisition. When this 
activity coincides with thalamocortical spindle 
activity (field oscillation that can be measured 
by EEG, at a frequency of around 12 – 14 Hz), 
transfer of information from the hippocampus 
to the neocortex is facilitated. 
Another key feature of SWS is the occurrence 
of slow oscillations resulting in ‘down’ states, 
during which entire areas of the neocortex are 
silent, and ‘up’ states, during which neocortical 
activity is as active as during wakefulness. Slow 
oscillations impose a temporal framework 
– up states are a window for hippocampal 
ripples and spindles to occur synchronously 
[14]. When the hippocampal ripple event (and 
its concurrently reactivated memory trace) 
coincides with the thalamocortical spindle, 
this convergence of the two oscillatory events 
allows for the memory trace reactivation to 
be fed into neocortical networks [15,16]. This 
occurs repeatedly during up states, such that 
the new memory trace is persistently activated, 
and gradually redistributed to the neocortex, 
where eventually, it will become part of pre-
existing knowledge networks (see Figure 1).
Factors influencing memory 
consolidation and cognitive 
enhancing strategies
As with many neurological processes, a myriad 
of interacting neurotransmitter systems can 
be implicated. We will focus here on the 
critical involvement of acetylcholine (ACh) 
and dopamine, as these neurotransmitters 
are depleted in two of the commonest 
neurodegenerative diseases, AD and Parkinson’s 
disease. Many other factors influence memory 
consolidation including sleep, exercise, diet, 
other neurotransmitters and neuronal growth 
factors including brain-derived neurotrophic 
Figure 1.  Mechanism of information transfer between neocortex and subcortical regions, underlying memory 
consolidation during slow wave sleep (SWS). Illustration of human brain through mid-sagittal section 
(with brainstem and cerebellum removed from view). Areas of interest are pointed out: neocortex, 
thalamus and hippocampus (embedded within the temporal lobe, visible here in green). Schematic 
diagram depicts the temporal relationship between the sleep events of interest – the neocortical slow 
oscillation imposes a timing relationship upon subcortical events in the thalamus and hippocampus. 
Spindle and ripple events cannot occur during down states of the slow oscillation (indicated by in 
purple shaded areas contained by dashed lines). Inhibition is lifted during neocortical up states, 
allowing subcortical events to occur. Spindles are phase-locked to a certain region of the slow 
oscillation activity – in turn, the hippocampal sharp-wave ripples are also locked to a certain phase 
of the spindle oscillation (phase-locking shown by blue lines). Ripples co-occur with reactivation of 
memory trace within the hippocampus, and temporal alignment of these events allows hippocampal 
information to travel to neocortical networks (green line) via thalamocortical pathways. Inset, bottom 
left, depicts cross-section through the hippocampus. Subfields involved in the generation of the sharp 
wave ripple (SWR) event are indicated. Excitatory input from CA3 via Schaffer collaterals results in strong 
depolarisation within CA1, evoking sharp-wave and consequent ripple activity.
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factor (BDNF) and these will also be discussed 
along with their potential for modification. 
Acetylcholine 
ACh is an obvious starting point for a discussion 
on cognitive enhancement, as cholinesterase 
inhibitors – which act by increasing the levels of 
ACh – are the major licensed drugs for memory 
enhancement in AD [17]. The rationale for using 
these drugs was established along with the 
cholinergic hypothesis of memory dysfunction 
[18] on the basis of reduced cholinergic 
forebrain neurons in AD [19] and amnesia 
caused by antimuscarinic drugs [20]. However, 
cholinesterase inhibitors benet fewer than 
50% of those who take them, and patients 
often experience side effects. One of the 
limiting factors with the use of cholinesterase 
inhibitors is that they target all cholinergic 
receptors – both nicotinic and muscarinic. 
Different receptor subtypes have distinct, 
but overlapping functions, with nicotinic 
subtypes involved largely in attention and 
muscarinic subtypes underpinning memory 
[21]. Thus, cholinesterase inhibitors can boost 
both memory and attention and a wide range 
of other brain and body-wide functions in 
patients (which can often result in side-effects) 
rather than targeting specific memory deficits.
If we focus on the potential for targeted 
enhancement of memory consolidation 
in patients, the muscarinic subtypes are of 
particular importance [22]. Of subtypes M1-
5, M1 is of specific interest, especially when 
we consider the fact that these receptors are 
expressed in brain areas implicated in the two-
stage theory of memory , the hippocampus and 
neocortex [23]. M1-selective antagonists impair 
long-term, but not short-term memory [24,25]. 
In addition, a study looking at M1-selective 
knockout animals found no effect on early 
performance in spatial learning tasks; once 
the animal was tested after a delay, however, 
deficits became apparent in the M1-knockout 
but not the wild type animals, suggesting a 
critical role for the M1 receptor specifically in 
long-term consolidation, but not short-term 
memory [26]. Human work on M1 agonism and 
memory consolidation during sleep has shown 
effects on sleep, but no benefit to cognition 
[27,28]. However, newer more specific M1 
agonists are now available, and much of the 
previous work looked at healthy young controls 
[27] (raising the strong possibility of ceiling 
effects), rather than looking at patients with AD, 
or even healthy elderly participants. Therefore, 
we think there is scope for further exploratory 
clinical evaluation of M1 agonists to enhance 
memory consolidation.
One further potential area of interest 
for memory enhancement is targeting of 
cholinergic nuclei by deep brain stimulation. 
Deep brain stimulation is used routinely in 
patients with Parkinson’s disease [29] and 
less often in chronic pain and depression. 
There are small trials underway of deep brain 
stimulation of cholinergic networks in AD. 
Putative targets include the nucleus basalis of 
Meynert (brain stem cholinergic nucleus) [30] 
and fornix [31]. Further preliminary data in 
humans stimulating the entorhinal cortex has 
suggested memory can be enhanced [32] and 
mice with traumatic brain injury had improved 
memory after stimulation of the medial septal 
nucleus. Further work is needed to establish the 
optimum target for such stimulation and the 
precise risk vs. benefit ratio for patients.
So, while the modest benefit of cholinesterase 
inhibitors has tempered enthusiasm for 
cholinergic cognitive enhancement, it is still 
possible that targeted pharmacological or 
deep brain stimulation of cholinergic neurons 
or receptors may prove fruitful.
The role of dopamine and 
other monoamines in memory 
consolidation
How does the role of dopamine in memory 
consolidation differ from that of ACh? Animal 
work has suggested that dopamine is more 
involved in late memory consolidation (i.e. 
over hours) than early memory formation [33]. 
In addition, recent human data has suggested 
that dopamine might be important for long-
term memory consolidation rather than 
early memory retention [34,35]. One study in 
patients with Parkinson’s disease suggested 
that removal of exogenous dopamine impaired 
memory consolidation over one hour, but not 
over 20 minutes [35].
As well as being critical for longer term 
memory consolidation, dopamine may have 
a role in information selection prior to storage; 
potentiating memory traces for objects 
that are novel, rewarding or aversive and 
therefore, ensuring more biologically relevant 
information is stored e.g. [36]. Dopaminergic 
connections to the hippocampus come 
from the ventral tegmental area (VTA) and 
substantia nigra, interconnecting with brain 
regions processing the valence of incoming 
information. Regarding negative valence in 
particular, a dopamine receptor-dependent 
network has been suggested in rats, promoting 
the retention of information about aversive 
stimuli, presumably so danger can be avoided 
[37]. Therefore, dopamine appears to have a 
specic role in late memory consolidation and 
enhancing certain memories traces according 
to context. 
Methylphenidate and modanil act by 
increasing levels of dopamine and, to a lesser 
degree, noradrenaline, and can be prescribed 
for attention decit hyperactivity disorder 
(ADHD) [38-40]. In addition, both are gaining 
recognition as cognitive enhancers [41,42]. 
Indeed, methylphenidate has been found to 
increase cognitive performance, including 
specically memory consolidation, in healthy 
people without ADHD [43]. There is increased 
activity within the prefrontal cortex after 
taking methylphenidate [44] leaving open 
the possibility that prefrontal networks 
mediate part of the cognitive enhancement 
effect via a boost in alertness or processing 
capacity rather than a specic enhancement 
of memory circuits. Modafinil rescues memory 
consolidation in sleep deprived animals 
[45], and enhances memory consolidation in 
healthy humans [46]. However, mofadinil also 
acts via orexins [47] and the effects of the drug 
may be attributed in part by enhancement of 
wakefulness (and therefore attention) rather 
than directly exerting an effect on memory – 
hence its prescription in narcolepsy.
Amphetamine has been found to improve 
memory consolidation in rats [48,49]. It has 
also been found to  improve memory encoding 
[50] and consolidation in humans [51] and 
has therapeutic potential to rectify memory 
decits in patients with multiple sclerosis 
[52]. Its actions are certainly very interesting 
– it acts predominantly on dopaminergic 
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receptors, but at niche subtypes – those in the 
hippocampus (dopaminergic subtype 2 [D2] 
receptors) are not activated [53], with the main 
targets being the mesolimbic and mesocortical 
pathways [54,55]. It may seem, therefore, that 
its actions are not due to a direct effect on the 
memory system – rather, any improvement 
in performance may well be explained by 
increased motivation by recruitment of the 
reward/motivation networks, which may act 
to increase attention and salience, resulting in 
improved performance. However, intriguingly, 
amphetamine has also been shown to increase 
levels of ACh within the hippocampus [56] – an 
action thought to be mediated by its actions 
on the D1 receptor. Indeed, dopamine has 
been implicated in cholinergic release [57], 
and as we have explained, ACh is central in 
processing hippocampal-dependent memory 
– so dopamine may be acting not only via 
the reward pathways, but more directly by its 
effect on modulating hippocampal ACh, on the 
memory system. This may well be contributing 
to the memory-enhancing effects of the 
dopaminergic drugs discussed above. 
It is also interesting to note that 
administration of both modanil and 
amphetamine results in increased number of 
ripples during subsequent SWS [58]. This has 
been thus far attributed to ‘rebound’ of ripples 
following the increased wakefulness caused 
by these stimulant drugs. However, it may well 
be worth further investigating these effects 
to see if increase in ripples has any functional 
signicance matching to the purported 
cognitive benets of these drugs, particularly as 
increased ripple number is linked to increased 
consolidation. 
Brain-derived neurotropic factor 
(BDNF)
Of particular interest is that increases in BDNF 
link many of the non-invasive interventions 
described later in this review - most notably, 
exercise and calorie restriction (see later 
sections). BDNF acts upon neurones in a 
variety of mechanisms, from providing 
neuroprotective and supportive roles during 
development and maintenance throughout 
the neuronal lifespan, to also playing a role 
in neurite outgrowth and targeting, and the 
regulation of channels. BDNF exerts its effects 
via a variety of signalling pathways, although 
its acute application can also produce synaptic 
responses. In short, its beneficial actions on 
cognition are convoluted and numerous – 
we focus here on those that relate directly to 
memory consolidation. 
Interesting insights into the mechanisms 
behind memory consolidation have been 
revealed by studying BDNF.  For example, 
specifically 12-hours post-training, there is 
a stage of memory consolidation which is 
BDNF-dependent; inhibition by blocking either 
BDNF, or its downstream signalling pathway, 
has no effect on memory recall at 2 days, but 
does produce an impairment in performance 
when tested 7 days post-training - implying 
that this BDNF-mediated mechanism is 
specifically involved in a longer-term facet of 
memory consolidation [59]. Intriguingly, the 
production of BDNF seems to be instigated 
by VTA dopaminergic system. Infusion of a 
dopamine antagonist into the CA1 subfield of 
the hippocampus at 12 hours following initial 
learning impairs 7 day-later recall, while leaving 
2-day recall intact – seemingly impairing this 
same long-term consolidation mechanism. 
NMDA blockade in the VTA produced similar 
results. What is more, this impairment is 
ameliorated if the dopaminergic antagonist is 
accompanied by infusion of exogenous BDNF 
– this would suggest that BDNF production 
occurs downstream and in response to 
dopaminergic activation  [60].
BDNF is of particular importance for AD, as 
levels have been found to be decreased in AD 
patients, and exogenously increasing BDNF 
levels has potent benefits for memory. Its 
exogenous infusion has been found to induce 
neurogenesis in rats [61], and in rodent models 
of AD prevents neuronal loss, reverses loss 
of synapses, and restores memory function. 
There are similar benets in aged rats and 
primates, where age-related loss of neurones 
and memory function is not only prevented, 
but restored by infusion of BDNF post-onset 
of decline [62]. This does provide a potentially 
promising opportunity for therapy, a means 
by which to kindle the brain’s potential for 
neurorestoration in order to ameliorate memory 
loss seen by neurodegeneration. Pioneering 
work currently underway in Bristol involves 
insertion of a permanent cerebral catheter 
and skull port into patients with Parkinson’s 
disease, to deliver pulsed glial cell derived 
neurotrophic factor (Whone et al. unpublished, 
[63]). This potentially opens up the possibility 
of delivering neurotrophic factors through the 
blood brain barrier in other conditions such as 
AD, both for neurorestoration and cognitive 
enhancement.
Sleep, and its manipulation, as a 
cognitive enhancer
As discussed above, we know that signicant 
memory consolidation occurs during sleep 
and therefore therapeutic modications to 
sleep to enhance memory are the subject of 
investigation. In Drosophila, it is possible to 
induce sleep remotely by inducing genetically-
controlled expression of temperature-gated 
cation channels at specic brain sites of interest, 
and controlling room temperature. This, in 
turn, has been shown to cause enhancements 
in memory [64].  Whilst such methodology 
of course cannot be directly recapitulated in 
humans, the parallel form of this is by inducing 
sleep through pharmacological means. 
Certain hypnotics, for instance, have been 
found to enhance memory, which may be 
mediated through their sleep-inducing 
properties. Gaboxadol (otherwise known as 
4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-
3-ol [THIP]) has been used as an effective 
treatment for sleep disorders  [65], and has also 
been found to increase SWS [66]– making it a 
promising therapeutic target. However, given 
that its effects on memory are thus far mixed 
[65,67] and its effect on sleep EEG activity varies 
greatly between genders [68], further, more 
detailed investigation is certainly warranted.  
Another strategy is to target SWS and slow 
oscillations in order to evoke some benet 
to memory consolidation. Indeed, this does 
seem extremely promising – one way to do 
this has been by using transcranial magnetic 
stimulation (TMS) allowing for a more 
focussed intervention than can be afforded 
by pharmacological methods. This has been 
successful in increasing slow oscillations in 
rodents and humans [69] as well as eliciting 
corresponding enhancements in memory 
Translational Neuroscience
Brought to you by | University of Bristol
Authenticated
Download Date | 10/3/16 5:37 PM
452
consolidation [70]. Another intriguing method 
being explored is the induction of slow 
oscillations by using auditory cues. Here, the 
auditory stimulation is played during SWS, 
using low frequency range-auditory cues to 
augment the oscillatory activity of the < 1 Hz 
slow oscillations. This has, indeed, been found 
to increase the amount of slow-oscillations, 
but results were sometimes mixed [71]. More 
recently, however, a study in healthy humans 
[72] used online monitoring of slow oscillations 
in order to administer the auditory cue in phase 
with the ongoing slow wave activity. Playing 
such cues produced reliable increases in slow 
oscillations, and a corresponding increase 
in memory consolidation, above that which 
was found in unaltered sleep. This is a very 
appealing nding, given that it indicates very 
promising outcomes can be attained from 
such a non-invasive mechanism, without any 
pharmacological or neurosurgical intervention, 
and without the side-effects of TMS. These 
benets were found in young healthy human 
subjects, but the merits are yet to be assessed 
in elderly or AD populations.
Exercise
There are a plethora of studies clearly illustrating 
that physical activity improves hippocampal 
function. Importantly, this improvement 
is not solely due to temporarily improved 
blood ow to the brain, but it has a robust 
neurophysiological basis, in the promotion of 
neurogenesis within the hippocampus (e.g., 
[73,74]). Neurogenesis is also accompanied 
by an increased neurite outgrowth, hence 
increased connectivity. Moreover, exercise 
also induces brain angiogenesis  [75], thereby 
promoting a positive cycle for brain function. 
Hippocampal volume is also seen to increase 
in human subjects with physical activity – for 
instance, level of physical tness has been 
linked with a higher hippocampal volume 
in children [76]. A multitude of studies 
demonstrate that this exercise-induced 
change also has its functional benets,  such as 
improved memory in animals [77] and healthy 
young human participants [78]. 
Ageing is accompanied by a decrease in 
neurogenesis in animals [79,80], and imaging 
in humans demonstrates that hippocampal 
volume is decreased with age [81]. Exercise, 
however, can ameliorate this – it improves spatial 
memory that normally deteriorates with age [77], 
and there is larger hippocampal volume in older 
adults with higher fitness [76]. This suggests that 
despite there being an age-related decline, there 
exists nevertheless a window of plasticity that 
can be harnessed through the beneficial effects 
of physical training.
Exercise is also a promising therapeutic aid. 
When looking at a mouse-models of AD (3xTg), 
aerobic exercise was found to decrease the 
symptoms and development of dementia  [82] 
– moreover, while neurogenesis is normally 
impaired in this mouse model, it was actually 
restored to the extent of being comparable 
with wildtype control animals, after exercise 
[83]. This restoration of neurogenesis occurred 
once the AD-like symptoms were underway, 
revealing a potential for not only a delay of 
the symptoms, but actually a reversal. In a 
study of mild cognitive impairment (MCI) 
patients [84], those in the control condition 
found their declarative memory deteriorated 
after six months, as the course of the disease 
progressed. Strikingly, however, those in the 
exercise conditions had memory which was not 
only preserved after six months, but actually 
improved compared to baseline. There have 
also been exercise-instigated improvements 
reported in other studies involving adults 
who are at risk of AD [85]. Furthermore, one 
intriguing study suggests specic types 
of physical activity can differentially affect 
individual facets of memory; in MCI patients, 
verbal memory was improved by aerobic 
exercise, but spatial memory was improved 
by both aerobic and resistance training [84]. 
Animal work suggests a putative mechanism 
for these differential effects. In rats, aerobic 
exercise training increased insulin-like growth 
factor 2 (IGF-2), while resistance training 
exercised rats were found to have higher levels 
of BDNF [86]. Along with BDNF, IGF-2 may be 
an important factor in memory processes [87].
Therefore, the relationship between memory 
consolidation and physical activity is now 
well-established, and provides an enticing 
opportunity for memory enhancement through 
exercise, for both healthy and pathological 
populations. 
Diet 
Glucose
Glucose appears to be especially important 
for hippocampal-dependent memory [90,91], 
and for demanding tasks [92-94]. After 
awakening, blood glucose levels in the brain 
are relatively low [88], and  improvements in 
working memory have been demonstrated 
upon glucose administration – regardless of 
whether blood glucose levels were depleted 
upon time of administration [89].  Moreover, 
this increase in blood glucose is dissociable 
from benets in attention alone, as memory 
performance benets both when glucose is 
administered before or after learning, and 
attention would only be a relevant factor at 
the point of learning rather than afterwards. 
Interestingly, the elderly population seem to 
derive more benet in memory function from 
increasing glucose compared to healthy young 
participants [90]. The primary site of action or 
effects of glucose has been proposed to the 
hippocampus, where it may be involved in ACh 
synthesis, which in itself is a prominent player 
in memory, and target for therapeutics (as 
discussed in section ‘Acetylcholine’). It should 
be noted that although raised glucose in the 
short-term may boost cognition, persistently 
increased glucose, such as in poorly controlled 
diabetes mellitus, results in impaired cognitive 
function due to various mechanisms, including 
cerebrovascular disease.
Calorie Restriction
Calorie restriction (CR) is a dietary regime 
involving reducing calorie intake by around 
10 – 30%. There are various methods by which 
this restriction can be achieved – by reducing 
daily food intake, by alternate day fasting, 
or by intermittent fasting [95]. Although it 
may seem somewhat counterintuitive at rst 
glance, inhibiting intake in this way actually 
has profound, well-documented beneficial 
results. It is most well-known in the literature as 
having longevity-enhancing effects, something 
which has been demonstrated in a wide range 
of organisms [96,97], and it also acts to delay 
age-related diseases, and a combination of 
both these effects have been demonstrated in 
rodents [98] and rhesus monkeys [99]. CR has 
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been found to benecially alter the expression 
of synaptic proteins that would normally be 
reduced by ageing [100] and ameliorates the 
effects of age-related cognitive decline in 
rodents by increasing levels of BDNF. Even aged 
rats that underwent late-onset CR had a degree 
of rescue of function [101]. CR protects against 
neurodegeneration, increases neurogenesis 
and memory performance, and decreases 
amyloid beta (Aβ) plaques in animal models of 
AD [102,103]. The mechanism for improvement 
through CR is thought to involve sirtuins (SIRT), 
which may, among other things, mediate 
neurogenesis.  Intriguingly, SIRT are also 
involved in up-regulation of ketones, which 
have been found to have neuroprotective 
effects [104], and are of therapeutic interest, 
having been suggested to benet in healthy 
people and  AD patients [105,106].
How do we reconcile the conflicting 
ndings that that both increased glucose and 
restricted dietary intake have beneficial effects 
on cognition and memory? One possibility is 
that the caloric intake restriction may not be 
reflecting the effects of decreased diet per se, 
but actually, the benets of not excessively 
indulging. It may well be that benefit of CR 
on memory is not due to any inherent benet 
of reducing calorie intake – any benets in 
memory are, rather, seen as a contrast to the 
control group, which is allowed to eat freely 
and may be relatively overeating. However, 
the specic pathways and proteins associated 
with CR, and their isolated benets, make this 
explanation less likely.  It is now emerging that 
the benets of CR, such as neuroprotection in 
AD, can be elicited by periods of hunger alone, 
in the absence of reducing overall calories 
[107]. This suggests that it is the period of 
hunger, and associated signalling pathways 
including SIRT, that are beneficial in the longer 
term, while briey raised glucose levels give a 
shorter term boost to cognition.
Polyunsaturated fatty acids
Omega-3 fatty acids are emerging as a crucial 
factor for neuronal health and function. 
Observed at the mechanistic level, the 
importance of omega-3 fatty acids becomes 
readily apparent – they are central to the 
development and maintenance of neurones 
and synaptic function [108]. It follows that 
rats with low omega-3 intake had decreased 
neuronal plasticity [109], while animals given 
omega-3 within their diet have increased 
BDNF expression within the hippocampus and 
neocortex [110], which are key sites for memory 
consolidation. 
An omega-3 fatty acid enriched diet also has 
therapeutic potential for AD – when given to the 
3xTg mouse model of AD, the loss of neurones 
within the entorhinal cortex was reduced, and 
memory decit development was delayed 
compared to controls [111]. Administration of 
omega-3 fatty acids in another mouse model 
(Tg2576) allowed for increased synaptic integrity, 
and again, manifested with a behavioural 
improvement – memory performance in the 
Morris water maze was increased.
Conclusion
There is a range of non-invasive, easy to 
implement factors, which have been robustly 
proven to enhance memory – increases in 
physical exercise, better-quality sleep, and 
dietary considerations. In addition, there are 
several very promising lines of pharmacological, 
neurosurgical and other interventional 
research that could benet individual patients 
and reduce the huge socioeconomic burden 
of dementia. Therapeutic research not only has 
potential for patient benet, but in turn informs 
our understanding of the complex networks 
underpinning normal memory consolidation.
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